ImageneBio (IMA) Equity Average (2020 - 2025)

ImageneBio has disclosed Equity Average across 6 years of filings, most recently posting $136.5 million for Q4 2025.

• Equity Average for Q4 2025 came in at $136.5 million, up 187.12% year-over-year; the trailing twelve-month figure through Dec 2025 was $136.5 million (up 187.12% YoY), and the FY2025 annual result was -$13.7 million, up 90.43% from the prior year.
• Equity Average came in at $136.5 million for Q4 2025 at ImageneBio, up from -$20.3 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $222.0 million in Q2 2021 to a low of -$175.0 million in Q2 2025.
• The 5-year median for Equity Average is $138.7 million (2023), against an average of $52.9 million.
• Across the five-year window, Equity Average jumped 415.48% in 2021 and slumped 1171.69% in 2024, its largest moves.
• ImageneBio's Equity Average stood at $205.6 million in 2021, then decreased by 25.63% to $152.9 million in 2022, then tumbled by 90.44% to $14.6 million in 2023, then plunged by 1171.69% to -$156.7 million in 2024, then soared by 187.12% to $136.5 million in 2025.
• The last three Equity Average figures came in at $136.5 million (Q4 2025), -$20.3 million (Q3 2025), and -$175.0 million (Q2 2025), per Business Quant data.